Pathology of the digestive system organs in post-COVID syndrome according to autopsy data from 2021—2024
- 27 January 2026
- journal article
- abstracts
- Published by Media Sphere Publishing Group in Russian Journal of Archive of Pathology
- Vol. 88 (1) , 52-59
Abstract
Objective. Clinical and morphologic analysis of pathologic changes of digestive system organs in COVID-19 patients according to autopsy data of 2021—2024. Material and methods. A retrospective clinical and morphologic analysis of data from 69 autopsies of patients who underwent COVID-19 (confirmed by polymerase chain reaction test) and had symptoms of digestive system lesions, according to clinical data, was performed. The data of case histories, autopsies, pathologoanatomic diagnoses and causes of death of patients were studied. Microscopic studies of tissue samples of stomach, intestine, liver, pancreas were performed. Immunohistochemical study with antibodies CD3, CD45, CD68, spike- and nucleocapsid-protein SARS-CoV-2 was performed. Results. According to autopsy data, pathologic changes of the stomach that first developed and pre-existing more than 3 months after SARS-CoV-2 infection were detected in 49 (71.01%) of 69 cases. Among them, chronic superficial gastritis was the most common with 17 (34.99%) observations and acute stress-induced gastric erosions and ulcers with 13 (26.53%). Small and large intestinal lesions were seen in 15 (30.61%) cases, among which intestinal adenocarcinomas predominated with 6 (40.00%), colonic diverticula and chronic lymphocytic colitis with 3 (20.00%) cases each. Liver pathology, new-onset and pre-existing, was present in 100.00% cases: muscadic liver 45 (65.22%), massive liver necrosis (7.25%), hepatic steatosis and steatohepatitis (26.09%), brown atrophy (8.70%). Pancreatic lesions, new-onset and pre-existing, were detected in 57 (82.60%) cases. Among them, sclerosis and lipomatosis were more frequently registered in type 2 diabetes mellitus — 46 (80.70%) observations, pancreonecrosis — 11 (19.30%). Conclusions. Gastric, intestinal, liver, and pancreatic pathology in COVID-19 patients may be either first-onset or preexisting. The detected persistence of nucleocapsid and spike proteins of the virus in tissues may cause direct and autoimmune tissue damage, leading to the development of new and progressive chronic diseases of the digestive organs.Keywords
This publication has 21 references indexed in Scilit:
- Incidence of persistent SARS-CoV-2 gut infection in patients with a history of COVID-19: Insights from endoscopic examinationEndoscopy International Open, 2023
- Chronic biopsy proven post‐COVID myoendocarditis with SARS‐Cov‐2 persistence and high level of antiheart antibodiesClinical Cardiology, 2022
- Molecular consequences of SARS-CoV-2 liver tropismNature Metabolism, 2022
- Could SARS-CoV-2 Spike Protein Be Responsible for Long-COVID Syndrome?Molecular Neurobiology, 2022
- Clinical and laboratory findings of COVID-19: A systematic review and meta-analysisJournal of the Formosan Medical Association, 2021
- Post-acute COVID-19 syndromeNature Medicine, 2021
- Pathological findings in the postmortem liver of patients with coronavirus disease 2019 (COVID-19)Human Pathology, 2021
- Pathophysiological mechanisms of liver injury in COVID‐19Liver International, 2020
- SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19Journal of Hepatology, 2020
- The force awakens: metastatic dormant cancer cellsExperimental & Molecular Medicine, 2020